We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
Among them, Illumina (ILMN - Free Report) , Tempus AI (TEM - Free Report) , and Novartis (NVS - Free Report) have upgraded their FY26 guidance, reflecting continued momentum and improving expectations for the rest of the year.
Illumina Sees Strong Demand
Illumina, a leading provider of DNA sequencing and genomic analysis technologies, posted quarterly revenue of $1.13 billion, reflecting 4.2% YoY growth. Adjusted EPS, excluding tariff refunds, came in at $1.44, growing 7% from the same period last year.
Importantly, healthy clinical demand and strong NovaSeq X placements helped underpin the results, with management now expecting FY26 revenue of $4.64-$4.66 billion, up $30 million at the midpoint from its prior guidance. The company also raised its adjusted EPS outlook to $5.40-$5.45 from $5.30-$5.40 previously, reflecting continued confidence in the earnings picture.
Tempus AI Delivers Record Revenue
Tempus AI, which utilizes artificial intelligence and data to advance precision medicine, delivered another record quarter, with revenue climbing 23% YoY to $411.5 million.
Growth was particularly strong throughout its Data & Applications business, where sales climbed 33% YoY to $108.1 million. Oncology testing volumes also reflected notable strength, growing 32% from the same period last year.
Given the momentum, management raised its FY26 revenue guidance to $1.60-$1.605 billion, suggesting roughly 25% annual growth. Its adjusted EBITDA outlook remained unchanged at approximately $65 million.
Novartis Raises Profit Outlook
Novartis, a global pharmaceutical giant, also delivered a constructive quarterly release, with growth from its priority brands and newer treatments helping offset generic competition.
The company raised its FY26 core operating income outlook to flat-to-low-single-digit growth, improving from its prior expectation for a low-single-digit decline. Its full-year sales outlook remained unchanged, with management still expecting low-single-digit growth.
The improved profitability outlook is undoubtedly encouraging, particularly given the generic competition that has weighed on portions of its portfolio.
Bottom Line
The Q3 earnings cycle has delivered several positives for healthcare investors, with Illumina (ILMN - Free Report) , Tempus AI (TEM - Free Report) , and Novartis (NVS - Free Report) all raising their FY26 guidance.
View the Zacks #1 Rank List
Image: Bigstock
3 Stocks to Watch Following Guidance Upgrades
The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
Among them, Illumina (ILMN - Free Report) , Tempus AI (TEM - Free Report) , and Novartis (NVS - Free Report) have upgraded their FY26 guidance, reflecting continued momentum and improving expectations for the rest of the year.
Illumina Sees Strong Demand
Illumina, a leading provider of DNA sequencing and genomic analysis technologies, posted quarterly revenue of $1.13 billion, reflecting 4.2% YoY growth. Adjusted EPS, excluding tariff refunds, came in at $1.44, growing 7% from the same period last year.
Importantly, healthy clinical demand and strong NovaSeq X placements helped underpin the results, with management now expecting FY26 revenue of $4.64-$4.66 billion, up $30 million at the midpoint from its prior guidance. The company also raised its adjusted EPS outlook to $5.40-$5.45 from $5.30-$5.40 previously, reflecting continued confidence in the earnings picture.
Tempus AI Delivers Record Revenue
Tempus AI, which utilizes artificial intelligence and data to advance precision medicine, delivered another record quarter, with revenue climbing 23% YoY to $411.5 million.
Growth was particularly strong throughout its Data & Applications business, where sales climbed 33% YoY to $108.1 million. Oncology testing volumes also reflected notable strength, growing 32% from the same period last year.
Given the momentum, management raised its FY26 revenue guidance to $1.60-$1.605 billion, suggesting roughly 25% annual growth. Its adjusted EBITDA outlook remained unchanged at approximately $65 million.
Novartis Raises Profit Outlook
Novartis, a global pharmaceutical giant, also delivered a constructive quarterly release, with growth from its priority brands and newer treatments helping offset generic competition.
The company raised its FY26 core operating income outlook to flat-to-low-single-digit growth, improving from its prior expectation for a low-single-digit decline. Its full-year sales outlook remained unchanged, with management still expecting low-single-digit growth.
The improved profitability outlook is undoubtedly encouraging, particularly given the generic competition that has weighed on portions of its portfolio.
Bottom Line
The Q3 earnings cycle has delivered several positives for healthcare investors, with Illumina (ILMN - Free Report) , Tempus AI (TEM - Free Report) , and Novartis (NVS - Free Report) all raising their FY26 guidance.